Quantitation of human immunodeficiency virus type 1 group O load in plasma by measuring reverse transcriptase activity.

Abstract

We have evaluated the use of an ultrasensitive reverse transcriptase (RT) activity assay to monitor plasma viremia in two human immunodeficiency virus type 1 (HIV-1) group O-infected patients treated with stavudine, lamivudine, and indinavir. After a initial decline in RT levels observed at 4 weeks of therapy, RT-based plasma viremia returned to baseline values at 28 or 44 weeks of treatment. The rebound in levels of RT activity was associated with the detection of phenotypic resistance to lamivudine and with the Met184Val mutation. Analysis of RT activity in plasma provides a sequence-independent means of monitoring virus loads in HIV-1 group O-infected patients.

• Authors: J G García Lerma, V Soriano, A Mas, M E Quiñones-Mateu, E J Arts, W Heneine
• Journal: Journal of clinical microbiology (J Clin Microbiol) Vol. 38 Issue 1 Pg. 402-5 (Jan 2000) ISSN: 0095-1137 [Print] United States
• PMID: 10618125 (Publication Type: Case Reports, Journal Article)

Chemical References

• Anti-HIV Agents
• Lamivudine
• Indinavir
• Stavudine
• HIV Reverse Transcriptase

Topics

• Adult
• Anti-HIV Agents (therapeutic use)
• Female
• Guinea
• HIV Infections (blood, drug therapy, enzymology)
• HIV Reverse Transcriptase (blood)
• HIV-1 (classification, enzymology)
• Humans
• Indinavir (therapeutic use)
• Lamivudine (therapeutic use)
• Male
• Middle Aged
• Molecular Sequence Data
• Spain
• Stavudine (therapeutic use)
• Viral Load
• Viremia (drug therapy)